By Billy Candra 
Deciding whether to start hormone therapy during the menopause transition, the life phase that’s the bookend to puberty and when a woman’s menstrual cycle stops, is a hotly debated topic, often fraught with conflicting information and historical controversy. While hormone therapy (HT), involving the replacement of hormones previously produced by the body with synthetic medication, is widely recommended to manage bothersome symptoms like hot flashes and night sweats, persistent confusion has existed regarding its long-term effects, particularly on cardiovascular health. However, a significant new study, spearheaded by Matthew Nudy, an assistant professor of medicine at the Penn State College of Medicine, suggests that long-term use of estrogen-based hormone therapies may, in fact, have beneficial effects on heart health. This multi-institutional research, which meticulously analyzed data from hormone therapy clinical trials within the extensive Women’s Health Initiative (WHI), found compelling evidence that estrogen-based HT improved several key biomarkers associated with cardiovascular health over an extended period. Most notably, the study points to a potential role for hormone therapy in lowering levels of lipoprotein(a), a genetic risk factor strongly linked to an elevated risk of heart attack and stroke, offering a promising avenue in cardiovascular disease prevention for a specific cohort of women.
The Evolving Landscape of Menopause and Hormone Therapy
Menopause marks a profound physiological shift in a woman’s life, typically occurring around the age of 51, though the transition, known as perimenopause, can begin years earlier. This phase is characterized by a natural decline in ovarian function, leading to a significant reduction in estrogen and progesterone production. The symptoms associated with menopause are diverse and can severely impact quality of life, ranging from vasomotor symptoms like hot flashes and night sweats, which affect up to 80% of menopausal women, to sleep disturbances, mood changes, vaginal dryness, and bone density loss.
Beyond these immediate discomforts, the hormonal changes accompanying menopause usher in another major health shift: an increased risk of cardiovascular disease (CVD). Estrogen, before menopause, plays a protective role in women’s cardiovascular systems, influencing cholesterol levels, maintaining blood vessel elasticity, and regulating blood pressure. The decline in estrogen can lead to adverse changes in lipid profiles (increased LDL "bad" cholesterol, decreased HDL "good" cholesterol), elevated blood pressure, and an acceleration of plaque buildup (atherosclerosis) in blood vessels, all of which substantially increase the risk of heart attack and stroke. Indeed, CVD becomes the leading cause of death for women post-menopause, surpassing all cancers combined.
The debate surrounding hormone therapy’s safety and efficacy, particularly concerning cardiovascular health, has a complex and often tumultuous history. For decades, HT was widely prescribed for menopausal symptoms and even for preventing chronic diseases. This practice underwent a dramatic shift in the early 2000s with the publication of initial findings from the Women’s Health Initiative (WHI), a large-scale, long-term national study focused on menopausal women. The WHI’s initial reports, particularly from its estrogen-plus-progestin trial in 2002, indicated an increased risk of breast cancer, heart disease, stroke, and blood clots in women taking HT. These findings led to a sharp decline in HT prescriptions, widespread fear among patients and physicians, and a significant re-evaluation of its use.
Re-examining the WHI Data: A Nuanced Perspective
In the two decades since the initial WHI reports, subsequent re-analyses and a deeper understanding of the study’s design and participant demographics have begun to paint a more nuanced picture. Crucially, the average age of women enrolled in the WHI trials was 63, with many starting HT well past the onset of menopause. This factor led to the development of the "timing hypothesis," which posits that hormone therapy may be beneficial or at least safer when initiated closer to the onset of menopause (typically within 10 years of the final menstrual period, or before age 60), often referred to as the "window of opportunity." Conversely, initiating HT much later, when atherosclerotic plaques may already be established, could potentially exacerbate existing cardiovascular conditions rather than prevent them.
It is within this evolving context that Nudy and his multi-institutional team undertook their latest investigation, seeking to clarify the long-term effects of HT on cardiovascular biomarkers. Prior research in the field had primarily focused on short-term effects, leaving a significant gap in understanding how these therapies influence heart health over an extended period. Their findings, published in the esteemed journal Obstetrics & Gynecology, contribute significantly to bridging this knowledge gap, providing additional guidance for both patients and clinicians navigating these complex decisions.
"The pendulum has been swinging back and forth as to whether hormone therapy is safe for menopausal women, especially from a cardiovascular disease perspective," Nudy remarked, highlighting the persistent uncertainty. "More recently, we’re recognizing that hormone therapy is safe in younger menopausal women within 10 years of menopause onset, who are generally healthy and who have no known cardiovascular disease." This statement underscores the shift towards a more individualized approach to HT, emphasizing patient selection and timing.
Methodology: A Deep Dive into Cardiovascular Biomarkers
The research team meticulously analyzed biomarkers associated with cardiovascular health over an impressive six-year period. Their dataset was derived from a subset of women who had participated in an oral hormone therapy clinical trial, a component of the original WHI study. Participants, post-menopausal women aged between 50 and 79 at the time of assignment, were randomly allocated to one of two groups: an estrogen-only group (for women who had undergone a hysterectomy and thus did not require progesterone to protect the uterus) and an estrogen-plus-progesterone group. Blood samples were collected at baseline and at one, three, and six-year intervals, allowing for a comprehensive longitudinal analysis. In total, the team analyzed samples from 2,696 women, representing approximately 10% of the total participants in that specific WHI trial. This rigorous methodology allowed the researchers to track changes in a range of cardiovascular markers over a substantial duration.
Key Findings: Positive Shifts in Cardiovascular Health Markers
The study revealed several compelling findings regarding the beneficial effects of hormone therapy on most cardiovascular biomarkers across both the estrogen-only and estrogen-plus-progesterone groups over time.
- Lipid Profile Improvements: Levels of LDL cholesterol, often dubbed the "bad" cholesterol due to its association with arterial plaque buildup, were significantly reduced by approximately 11% in both groups. Simultaneously, total cholesterol also decreased, while HDL cholesterol, the "good" cholesterol known for its protective role in clearing cholesterol from arteries, increased by 13% in the estrogen-only group and 7% in the estrogen-plus-progesterone group. These changes represent a favorable shift in the lipid profile, indicative of a reduced risk of atherosclerosis.
- Insulin Resistance Reduction: The study also observed a decrease in insulin resistance in both groups. Insulin resistance is a precursor to type 2 diabetes and is independently linked to an increased risk of cardiovascular disease. Improving insulin sensitivity is a significant positive outcome for metabolic and cardiovascular health.
However, the study also noted some less favorable changes. Triglycerides, a type of fat in the blood, and coagulation factors, proteins essential for blood clot formation, were found to increase. These findings are consistent with some previous research on oral estrogen therapy and warrant careful consideration in clinical practice, as elevated triglycerides and increased clotting potential can pose risks.
The Lipoprotein(a) Revelation: A Game Changer?
Perhaps the most surprising and impactful discovery of this research concerned lipoprotein(a) [Lp(a)], a type of cholesterol molecule. The study found that levels of Lp(a) decreased significantly: by 15% in the estrogen-only group and an even more pronounced 20% in the estrogen-plus-progesterone group.
Lipoprotein(a) is a particularly insidious genetic risk factor for cardiovascular disease. Unlike other types of cholesterol, whose concentrations can be influenced by lifestyle factors such as diet, exercise, and smoking, Lp(a) levels are primarily determined by genetics. High concentrations of Lp(a) are strongly associated with an increased risk of heart attack and stroke, often at a younger age, and also contribute to the risk of aortic stenosis, a condition where calcium buildup narrows a heart valve. Globally, approximately 1 in 5 people have elevated Lp(a), making it a widespread yet often overlooked risk factor.
"As a cardiologist, this finding is the most interesting aspect of this research," Nudy stated, underscoring the clinical significance. "Currently, there are no medications approved by the Food and Drug Administration (FDA) specifically to lower lipoprotein(a). Here, we essentially found that oral hormone therapy significantly reduced lipoprotein(a) concentrations over the long-term." This observation is monumental because it identifies a readily available therapeutic option that can address a stubbornly high-risk factor for which no targeted treatments currently exist.
Intriguingly, when the research team examined the findings by self-reported racial and ethnic group, they discovered that the decrease in Lp(a) concentration was even more pronounced among participants with American Indian or Alaska Native ancestry (a remarkable 41% reduction) and Asian or Pacific Islander ancestry (a 38% reduction). Nudy acknowledged that the reasons for these steeper reductions in specific populations are not yet clear, but the team plans to investigate this further in future research studies. This differential response highlights the potential for personalized medicine approaches to HT.
Oral vs. Transdermal: Unpacking the Mechanism
Nudy also provided crucial context regarding the type of estrogen therapy used in the clinical trial: conjugated equine estrogens, a commonly prescribed form of oral estrogen therapy. He explained that oral hormone therapy, before being absorbed into the bloodstream, undergoes "first-pass metabolism" in the liver. This process, while effective, can potentially increase inflammatory markers, which Nudy suggested might explain the observed rise in triglycerides and coagulation factors.
This distinction is vital because newer formulations of estrogen hormone therapy, such as transdermal estrogen (administered through the skin via patches, gels, or sprays), bypass the first-pass metabolism in the liver. "There are now other common formulations of estrogen hormone therapy like transdermal estrogen," Nudy noted. "Newer studies have found that transdermal estrogen doesn’t increase triglycerides, coagulation factors or inflammatory markers." This insight suggests that transdermal HT might offer a cardiovascular safety profile superior to oral forms, particularly concerning thrombotic risk and triglyceride elevation, thereby expanding the options for women who might benefit from HT but have concerns about these specific side effects. This knowledge allows for more tailored treatment decisions, considering a woman’s individual risk factors and preferences.
Clinical Implications and Future Directions
The findings of this study significantly enrich the understanding of the complex interplay between hormone therapy and heart health. They reinforce the growing consensus that, for healthy women initiating HT within the "window of opportunity" (generally within 10 years of menopause onset or before age 60), the benefits of symptom management and potentially cardiovascular protection may outweigh the risks. However, the study also underscores that HT is not a one-size-fits-all solution.
For those considering menopause hormone therapy, Nudy strongly recommended undergoing a comprehensive cardiovascular disease risk assessment. This assessment is crucial even for individuals who have no history of heart attack, stroke, or diagnosed cardiovascular disease. Such an evaluation provides healthcare providers with invaluable information to consider the best and safest option for managing menopause symptoms, factoring in a woman’s unique health profile, risk factors, and personal preferences.
It is important to reiterate that, as Nudy noted, "Currently, hormone therapy is not FDA-approved to reduce the risk of coronary artery disease or stroke." While this research offers compelling evidence for beneficial cardiovascular effects, particularly regarding Lp(a), it does not alter current FDA indications. The primary approved use of HT remains the management of moderate to severe menopausal symptoms. However, studies like this contribute to a broader body of evidence that informs clinical guidelines and may, over time, lead to a re-evaluation of HT’s role in long-term health management.
The study’s insights into racial and ethnic differences in Lp(a) reduction also open new avenues for research, prompting questions about genetic predispositions, metabolic pathways, and how these interact with hormone therapy. Understanding these nuances could pave the way for more equitable and effective therapeutic strategies. Future studies will likely delve deeper into these specific populations and investigate the long-term outcomes associated with Lp(a) reduction via HT.
This collaborative work was supported by funding from the National Center for Advancing Translational Sciences. The extensive list of contributing authors includes Aaron Aragaki from Fred Hutchinson Cancer Center; Peter Schnatz and Xuezhi Jiang from Drexel University College of Medicine; JoAnn Manson from Brigham and Women’s Hospital, Harvard Medical School and Harvard T.H. Chan School of Public Health; Aladdin Shadyab from the University of California San Diego; Su Yong Jung from the University of California Los Angeles; Lisa Martin from The George Washington University; Robert Wild from the University of Oklahoma Health Sciences Center; Catherine Womack from the University of Tennessee Health Science Center; Charles Mouton from the University of Texas Medical Branch; and Jacques Rossouw, formerly of the National Heart, Lung, and Blood Institute at the National Institutes of Health. Their combined expertise was instrumental in navigating the complexities of this extensive dataset and producing findings that promise to reshape clinical discussions surrounding hormone therapy and women’s cardiovascular health.
